tiprankstipranks
Advertisement
Advertisement

DE:8F8 Stock Latest News

SynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
Company AnnouncementsSynAct extends U.S. patent exclusivity for lead RA therapy resomelagon to 2044
1d ago
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
PremiumCompany Announcements
SynAct Pharma’s AP1189 Trial Targets Viral Respiratory Risk: What Investors Should Watch
2d ago
8F8
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
PremiumCompany Announcements
SynAct Pharma AGM Confirms No Dividend and Renews Mandate for New Share Issues
2d ago
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
PremiumCompany Announcements
SynAct Pharma Details Q1 2026 Progress in Inflammation-Focused Biotech Strategy
18d ago
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
PremiumCompany Announcements
SynAct Pharma Clarifies Large Shareholder’s Erroneous Share Sale Order
19d ago
SynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
PremiumCompany AnnouncementsSynAct Pharma to Showcase Lead Inflammation Drug Ahead of Key Rheumatoid Arthritis Data
25d ago
SynAct Pharma convenes AGM and opts to retain earnings
Premium
Company Announcements
SynAct Pharma convenes AGM and opts to retain earnings
1M ago
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
Premium
Company Announcements
SynAct Pharma Finishes Phase 2b Dosing in Rheumatoid Arthritis Study
1M ago
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
PremiumCompany Announcements
SynAct Pharma Targets New Partnerships Ahead of Key Resomelagon Data
1M ago
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
PremiumCompany Announcements
SynAct Pharma Updates Nomination Committee Ahead of 2026 AGM
2M ago
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
PremiumCompany Announcements
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
2M ago
SynAct Pharma Raises Share Capital Through Directed Issue
PremiumCompany Announcements
SynAct Pharma Raises Share Capital Through Directed Issue
2M ago
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
PremiumCompany AnnouncementsSynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
3M ago
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
Premium
Company Announcements
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
3M ago
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
Premium
Company Announcements
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
3M ago
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
PremiumCompany Announcements
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
3M ago
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
PremiumCompany Announcements
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
3M ago
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
PremiumCompany Announcements
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
4M ago
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
PremiumCompany Announcements
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
4M ago
SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares
PremiumCompany AnnouncementsSynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares
4M ago
SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts
Premium
Company Announcements
SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts
4M ago
SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial
Premium
Company Announcements
SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >